Piramal Pharma Bets On Complex Drugs To Drive Future Growth
Piramal Pharma is aiming to boost earnings over the next two to three years by focusing on rising demand for complex drugs, particularly targeted cancer therapies. Chairperson Nandini Piramal said the company expects stronger growth as global interest in advanced treatments increases, especially in high-value segments like antibody-drug conjugates (ADCs).
The company generates about 55% of its revenue from contract drug manufacturing and is seeing improved demand as global biotech funding rebounds. According to Piramal, funding in the second half of the year rose sharply, leading to increased order inflows from both large pharmaceutical firms and biotech companies. Indian drugmakers are also benefiting from U.S. restrictions on biotech funding for Chinese competitors.
Despite reporting a 3% decline in fiscal 2026 revenue—driven by a 10% drop in its contract manufacturing business—Piramal expects revenue growth in the early-to-mid teens in the coming years. The company is prioritizing high-margin, complex therapies while avoiding crowded segments like generic weight-loss drugs, where pricing pressure and competition remain intense.
Pic courtesy: google/ images are subject to copyright
